Bilateral lung transplantation with intra- and postoperatively prolonged ECMO support in patients with pulmonary hypertension

Pereszlenyi, Arpad; Lang, Georg; Steltzer, Heinz; Hetz, Hubert; Kocher, Alfred; Neuhauser, Petra; Wisser, Wilfried; Klepetko, Walter
May 2002
European Journal of Cardio-Thoracic Surgery;May2002, Vol. 21 Issue 5, p858
Academic Journal
Objective: Lung transplantation for pulmonary hypertension (PH) is usually performed on cardiopulmonary bypass, with the disadvantage of full systemic anticoagulation, uncontrolled allograft reperfusion and aggressive ventilation. These factors can be avoided with intra- and postoperatively prolonged extracorporeal membrane oxygenator (ECMO) support. Patients and methods: Between February 1999 and March 2001, 17 consecutive patients with PH (systolic pulmonary artery pressure >70 mmHg) of different etiologies underwent bilateral lung transplantation (BLTX). There were 11 females and six males in the age range from 7 to 50 years (mean age, 28.4±12.9 years). Six patients were preoperatively hospitalized, four in the intensive care unit (ICU), one was on ECMO for 3 weeks pretransplantation, and one was resuscitated and bridged with ECMO for 1 week until transplantation. Femoral venoarterial ECMO support with heparin-coated circuits was set up after induction of anesthesia and discontinued at the end of surgery (n=3) or extended for 12 h median into the postoperative period (n=14). Postoperative ventilation pressure was kept below 25 mmHg. Allograft function at 2 h after discontinuation of ECMO, outcome and adverse events were monitored in all patients. Mean follow up time was 18±11.4 months. Results: The perioperative mortality was 5.9% (n=1). Arterial oxygen pressure measured 2 h after weaning from ECMO, and under standard mechanical ventilation with a peak pressure of 25 mmHg and inspired oxygen fraction of 0.4, was 157±28 mmHg. The mean pulmonary artery pressures were reduced to 29±3,4 from 66±15 mmHg before transplantation. Postoperative complications included rethoracotomy due to bleeding (n=4) and temporary left ventricular failure (n=4). Median ICU stay was 12 days. Incidence of rejection within the first 100 days was 0.4 per patient. Conclusion: BLTX with intraoperative and postoperatively prolonged ECMO support provides excellent initial organ function due to optimal controlled reperfusion and non-aggressive ventilation. This results in improved outcome even in advanced forms of PH.


Related Articles

  • Erratum.  // Advances in Pulmonary Hypertension;2016, Vol. 15 Issue 2, p112 

    A correction to the article "Pulmonary Arterial Hypertension: 'A Journey to Lung Transplant'" that was published in the previous issue is presented.

  • Lung Allocation Score Modification Proposal.  // Advances in Pulmonary Hypertension;Spring2012, Vol. 11 Issue 1, p52 

    The article informs that the Thoracic Organ Transplantation Committee will be reviewing the Lung Allocation Score (LAS) system for increasing the post transplant survival of patients with pulmonary arterial hypertension (PAH).

  • Erratum to: Preoperative Echocardiographic-Defined Moderate-Severe Pulmonary Hypertension Predicts Prolonged Duration of Mechanical Ventilation Following Lung Transplantation for Patients with COPD. Wrobel, Jeremy; Thompson, Bruce; Snell, Gregory; Williams, Trevor // Lung;Apr2013, Vol. 191 Issue 2, p227 

    A correction to the article "Preoperative Echocardiographic-Defined ModerateSevere Pulmonary Hypertension Predicts Prolonged Duration of Mechanical Ventilation Following Lung Transplantation for Patients with COPD," by Jeremy P. Wrobel and colleagues that was published in the 2013 issue is...

  • Pulmonary Hypertension and Lung Transplantation. Feltracco, Paolo; Serra, Eugenio; Barbieri, Stefania; Lunardi, Giacinto; Milevoj, Moira; Ori, Carlo // Current Hypertension Reviews;2008, Vol. 4 Issue 1, p17 

    Pulmonary hypertension (PH) is a disorder with poor prognosis sustained by progressive elevation of pulmonary vascular resistance to blood flow. It is a serious condition for which treatments exist but there is no cure. The main determinants are vasoconstriction, pulmonary vascular remodelling,...

  • Pulmonary acceleration time to optimize the timing of lung transplant in cystic fibrosis. Damy, Thibaud; Burgel, Pierre-R�gis; Pepin, Jean-Louis; Boelle, Pierre-Yves; Cracowski, Claire; Murris-Espin, Marl�ne; Nove-Josserand, Raphaele; Stremler, Nathalie; Simon, Tabassome; Adnot, Serge; Fauroux, Brigitte // Pulmonary Circulation;2012, Vol. 2 Issue 1, p75 

    Pulmonary hypertension (PH) may affect survival in cystic fibrosis (CF) and can be assessed on echocardiographic measurement of the pulmonary acceleration time (PAT). The study aimed at evaluating PAT as a tool to optimize timing of lung transplant in CF patients. Prospective multicenter...

  • Paradoxical Effect of Prostacyclin Infusion in a Patient with Primary Pulmonary Hypertension. Younger, Jared R.; Lui, Charles Y. // Angiology;May/Jun2004, Vol. 55 Issue 3, p341 

    Prostacyclin treatment successfully delays the need for lung transplantation in many patients with progressive primary pulmonary hypertension by vasodilating pulmonary arteries. However, the treatment of pulmonary hypertension with prostacyclin may cause a paradoxical increase in pulmonary...

  • CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH). McNeil, Keith; Dunning, John // Heart;Sep2007, Vol. 93 Issue 9, p1152 

    The article presents information on chronic thromboembolic pulmonary hypertension (CTEPH). Chronic pulmonary thromboembolic disease is a significant cause of severe pulmonary hypertension and is related with morbidity and mortality. CTEPH is the only cause of severe pulmonary transplantation...

  • Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Nunes, H.; Humbert, M.; Capron, F.; Brauner, M.; Sitbon, O.; Battesti, J-P.; Simonneau, G.; Valeyre, D. // Thorax;Jan2006, Vol. 61 Issue 1, p68 

    Background: Pulmonary hypertension (PH) is a rare complication of sarcoidosis, although it is not uncommon in advanced disease. Methods: A retrospective series of 22 sarcoidosis patients (16 men) of mean (SD) age 46 (13) years with PH was divided into two groups depending on the absence (stage...

  • Advances in the Management of Pediatric Pulmonary Hypertension. Oishi, Peter; Datar, Sanjeev A.; Fineman, Jeffrey R. // Respiratory Care;Sep2011, Vol. 56 Issue 9, p1314 

    Pulmonary hypertension is a rare disease in neonates, infants, and children, and is associated with substantial morbidity and mortality. An adequate understanding of the controlling pathophysiologic mechanisms is lacking. Moreover, a minority of research is focused specifically on neonatal and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics